Kintegral Advisory LLC Cuts Stake in Humana Inc. (NYSE:HUM)

Kintegral Advisory LLC decreased its stake in Humana Inc. (NYSE:HUM) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,732 shares of the insurance provider’s stock after selling 174 shares during the period. Kintegral Advisory LLC’s holdings in Humana were worth $950,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Creative Financial Designs Inc. ADV lifted its position in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Humana during the fourth quarter valued at approximately $30,000. Ashton Thomas Securities LLC purchased a new stake in shares of Humana during the third quarter valued at approximately $31,000. Your Advocates Ltd. LLP lifted its position in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. Finally, Atwood & Palmer Inc. boosted its stake in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after purchasing an additional 60 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

HUM has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Piper Sandler lifted their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Truist Financial raised their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Finally, Barclays upped their target price on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $285.68.

Humana Price Performance

HUM opened at $255.77 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company’s 50-day moving average price is $269.41 and its 200 day moving average price is $290.00. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The firm has a market cap of $30.80 billion, a price-to-earnings ratio of 25.71, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.38%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.